1 min read
Add as a preferred source on GoogleFoghorn Therapeutics Posts $0.80 Q3 GAAP EPS, $83.5 Million Revenue
Research and development expenses fell $1.2 million from a year earlier.
Foghorn Therapeutics Inc. reported third-quarter GAAP earnings per share of $0.80 and revenue of $83.5 million, while research and development expenses declined from a year earlier.
The results cover the three months ended Sept. 30, 2026.
Research and development expenses totaled $18.8 million during the quarter.
That was $1.2 million below the $20 million recorded in the three months ended Sept. 30, 2025.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.